Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: An important but poorly studied relationship

Journal of Endocrinological Investigation

Volumn 34, Issue 4, 2011, Pages 317-323

  Fusaro, M ^a   Crepaldi, G ^b   Maggi, S ^b   Galli, F ^c   D'Angelo, A ^a   Calo L ^a   Giannini, S ^a   Miozzo, D ^b   Gallieni, M ^d  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

Dialysis; Fractures; Menaquinone; Osteoporosis; Phylloquinone; Vascular calcifications

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; APOLIPOPROTEIN E; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; FARNOQUINONE; GLUTAMIC ACID; MATRIX GLA PROTEIN; MENAQUINONE; MENATETRENONE; OSTEOCALCIN; OSTEOPROTEGERIN; PHYTOMENADIONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN K GROUP; WARFARIN;

ANTIBIOTIC THERAPY; AORTA RUPTURE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE MASS; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CARBOXYLATION; CHRONIC KIDNEY DISEASE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; FRAGILITY FRACTURE; GENOTYPE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HIP FRACTURE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MORTALITY; NONHUMAN; ODONTOBLAST; OSTEOBLAST; OSTEOPOROSIS; PHAGOCYTE; PHOSPHORYLATION; REVIEW; SIDE EFFECT; STROKE; THROMBOGENESIS; THROMBUS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VERTEBRA FRACTURE; VITAMIN BLOOD LEVEL; VITAMIN K DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANIMALS; CALCINOSIS; FRACTURES, BONE; HUMANS; KIDNEY FAILURE, CHRONIC; MOLECULAR STRUCTURE; OSTEOCALCIN; RENAL DIALYSIS; VITAMIN K 1; VITAMIN K 2;

EID: 79958041319     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7353     Document Type: Review

References (77)

1. Shearer MJ. Vitamin K. Lancet 1995, 345: 229-34.
2. Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis 2000, 30: 298-307.
3. Bugel S. Vitamin K and bone health. Proc Nutr Soc 2003, 62: 839-43.
4. Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K. J Nutr 1998, 128: 785-8. (Pubitemid 28225505)
5. Kohlmeier M, Salomon A, Saupe J, Shearer MJ. Transport of vitamin K to bone in humans. J Nutr 996, 126 (Suppl): 1192S-6S.
6. Kohlmeier M, Saupe J, Schaefer K, Asmus G. Bone fracture history and prospective bone fracture risk of hemodialysis patients are related to apolipoprotein E genotype. Calcif Tissue Int 1998, 62: 278-81. (Pubitemid 28127943)
7. Krueger T, Westenfeld R, Ketteier M, Schurgers LJ, Floege J. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Kidney Int 2009, 76: 18-22.
8. Schurgers LJ, Teunissen KJ, Hamulyák K, Knapen MH, Vik H, Vermeer C. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood 2007, 109: 3279-83. (Pubitemid 46572513)
9. Nieves JW. Osteoporosis: the role of micronutrients. Am J Clin Nutr 2005, 81: 1232S-9S.
10. Fouque D, Vennegoor M, Ter Wee P et al. EBPG guideline on nutrition. Nephrol Dial Transplant 2007, 22 (Suppl 2): ii45-87.
11. Kohlmeier M, Saupe J, Shearer MJ, Schaefer K, Asmus G. Bone health of adult hemodialysis patients is related to vitamin K status. Kidney Int 1997, 51: 1218-21. (Pubitemid 27186549)
12. Pilkey RM, Morton AR, Boffa MB, et al. Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis 2007, 49: 432-9.
13. Neogi T, Booth SL, Zhang YQ, et al. Low vitamin K status is associated with osteoarthritis in the hand and knee. Arthritis Rheum 2006, 54: 1255-61. (Pubitemid 43672937)
14. Kohlmeier M, Saupe J, Drossel HJ, Shearer MJ. Variation of phylloquinone (vitamin K1) concentrations in hemodialysis patients. Thromb Haemost 1995, 74: 1252-4.
15. Schurgers U, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 2008, 100: 593-603.
16. Zebboudj AF, Imura M, Boström K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002, 277: 4388-94. (Pubitemid 34968705)
17. Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two Gla-containing proteins. J Cell Biol 2004, 165: 625-30. (Pubitemid 38765764)
18. Munroe PB, Olgunturk RO, Fryns JP, et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet 1999, 21: 142-4. (Pubitemid 29036302)
19. Meier M, Weng LP, Alexandrakis E, Rüschoff J, Goeckenjan G. Tracheobronchial stenosis in Keutel syndrome. Eur Respir J 2001, 17: 566-9. (Pubitemid 32600627)
20. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997, 386: 78-81. (Pubitemid 27130923)
21. Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care 2000, 3: 433-8.
22. Sigrist M, Bungay P, Taal MW, McIntyre CW. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 2006, 21: 707-14. (Pubitemid 43372919)
23. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002, 39: 695-701.
24. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342: 1478-83. (Pubitemid 30318271)
25. Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005, 46: 897-902. (Pubitemid 41505464)
26. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010, 77: 1098-106.
27. Genovesi S, Santoro A. Warfarin and stroke outcomes in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009, 20: 2090-2.
28. Schurgers LJ, Aebert H, Vermeer C, Bültmann B, Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease. Blood 2004, 104: 3231-2. (Pubitemid 39507140)
29. Krüger T, Floege J. Coumarin use in dialysis patients with atrial fibrillation-more harm than benefit? Nephrol Dial Transplant 2009, 24: 3284-5.
30. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998, 18: 1400-7. (Pubitemid 28421877)
31. Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 2000, 20: 317-27. (Pubitemid 30086086)
32. Howe AM, Webster WS. Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol 2000, 81: 51-6. (Pubitemid 30171501)
33. Holden RM, Sanfilippo AS, Hopman WM, Zimmerman D, Garland JS, Morton AR. Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol 2007, 20: 417-22.
34. Koos R, Krueger T, Westenfeld R, et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost 2009, 101: 706-13.
35. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin: results from National Registry of Atrial Fibrillation 2. Arch Intern Med 2006, 166: 241-6.
36. Mamdani M, Upshur RE, Anderson G, Bartle BR, Laupacis A. Warfarin therapy and risk of hip fracture among elderly patients. Pharmacotherapy 2003, 23: 1-4.
37. Booth SL, Mayer J. Warfarin use and fracture risk. Nutr Rev 2000, 58: 20-2.
38. Cranenburg EC, Vermeer C, Koos R, et al. The circulating inactive form of matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res 2008, 45: 427-36.
39. Schurgers U, Barreto DV, Barreto FC, et al. The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010, 5: 568-75.
40. Geleijnse JM, Vermeer C, Grobbee DE, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr 2004, 134: 3100-5.
41. Reichel H. No effect of vitamin K1 supplementation on biochemical bone markers in hemodialysis patients. Nephrol Dial Transplant 1999, 14: 249-50.
42. Małyszko J, Wołczyński S, Skrzydlewska E, Małyszko JS, Myśliwiec M. Vitamin K status in relation to bone in patients with renal failure. Am J Nephrol 2002, 22: 504-8.
43. Westenfeld R, Krüger T, Schlieper G, et al. Vitamin K2 supplementation reduces the elevated inactive form of the calcification inhibitor matrix GLA protein in hemodialysis patients. J Am Soc Nephrol 2008, 19: 11A (abstract)
44. Forli L, Bollerslev J, Simonsen S, et al. Dietary vitamin K2 supplement improves bone status after lung and heart transplantation. Transplantation 2010, 89: 458-64.
45. Sugimoto T, Yamakado M, Matsushita K, Iwamoto T, Tagawa H. Pharmacodynamics of menatetrenone and effects on bone metabolism in continuous ambulatory peritoneal dialysis patients. J Int Med Res 2002, 30: 566-75.
46. Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980, 66: 878-83.
47. Zhang R, Ducy P, Karsenty G. 1,25-dihydroxyvitamin D3 inhibits osteocalcin expression in mouse through an indirect mechanism. J Biol Chem 1997, 272: 110-6.
48. Szulc P, Chapuy MC, Meunier J, et al. Serum undercarboxylated osteocalcin is a marker of the risk of hip fractures in elderly women. J Clin Invest 1993, 91: 1769-74.
49. Nakao M, Nishiuchi Y, Nakata M, Kimura T, Sakakibara S. Synthesis of human osteocalcins: gamma-carboxyglutamic acid at position 17 is essential for a calcium-dependent conformational transition. Pept Res 1994, 7: 171-4.
50. Koshihara Y, Hoshi K. Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res 1997, 12: 431-8.
51. Ingram RT, Park Y, Clarke BL, Fitzpatrick LA. Age and gender-related changes in the distribution of osteocalcin in the extracellular matrix of normal male and female bone. Possible involvement of osteocalcin in bone remodeling. J Clin Invest 1994, 93: 989-97.
52. Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996, 382: 448-52.
53. Sasaki N, Kusano E, Takahashi H, et al. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab 2005, 23: 41-7.
54. Fusaro M, D'Angelo A, Gallieni M. Vertebral fractures in patients on dialysis: a clinically relevant problem with insufficient investigation. NDT Plus 2008, 1: 464-5.
55. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000, 58: 396-9.
56. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999, 33: 287-93.
57. Rodríguez-García M, Gómez-Alonso C, Naves-Díaz M, et al. Prevalence of vertebral fractures and aortic calcifications in hemodialysis patients: comparison with a population of the same age and sex. Nefrologia 2003, 23 (Suppl 2): 106-11.
58. Jamal SA, Gilbert J, Gordon C, Bauer DC. Cortical pQCT measures are associated with fractures in dialysis patients. J Bone Miner Res 2006, 21: 543-8.
59. Rodríguez-García M, Gómez-Alonso C, Naves-Díaz M, Díaz-López JB, Díaz-Corte C, Cannata-Andía JB, Asturias Study Group. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant 2009, 24: 239-46.
60. Riggs BL, Hodgson SF, O' Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990, 322: 802-9.
61. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semi-quantitative technique. J Bone Miner Res 1993, 8: 1137-48.
62. Guglielmi G, Diacinti D, van Kuijk C, et al. Vertebral morphometry: current methods and recent advances. Eur Radiol 2008, 18: 1484-96.
63. Guglielmi G, Stoppino LP, Placentino MG, D' Errico F, Palmieri F. Reproducibility of a semi-automatic method for 6-point vertebral morphometry in a multi-centre trial. Eur J Radiol 2009, 69: 173-8.
64. Arboleya L, Díaz-Curiel M, Del Río L, et al; OSTEOXPRESS study investigators. Prevalence of vertebral fracture in postmenopausal women with lumbar osteopenia using MorphoXpress(R) (OSTEOXPRESS Study). Aging Clin Exp Res 2010, 22: 419-26.
65. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285: 320-3.
66. Hasserius R, Karlsson MK, Nilsson BE, Redlund-Johnell I, Johnell O; European Vertebral Osteoporosis Study. Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int 2003, 14: 61-8.
67. Naves M, Rodríguez-García M, Díaz-López JB, Gómez-Alonso C, Cannata-Andía JB. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos Int 2008, 19: 1161-6.
68. Fusaro M, D'Angelo A, Scalzo G, Gallieni M, Giannini S, Guglielmi G. Vertebral fractures in dialysis: endocrinological disruption of the bone-kidney axis. J Endocrinol Invest 2010, 33: 347-52.
69. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000, 36: 1115-21.
70. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney lnt 2006, 70: 1358-66.
71. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006, 47: 149-56.
72. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ. Vitamin K and prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2006, 166: 1256-61.
73. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000, 15: 515-21.
74. Emaus N, Gjesdal CG, Almås B, et al. Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial. Osteoporosis Int 2010, 21: 1731-40.
75. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003, 349: 446-56.
76. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16: 1115-25.
77. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341: c3691.